XEXavier A. Erguera

Xavier A. Erguera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xavier A. Erguera has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Satisfaction and Treatment Burden Among Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine With and Without Viremia in Three US Ryan White Clinics

    by Katerina A Christopoulos, Alex Beckert, Caleb McCracken, Kaylin Dance, Sophie Plotkin, Lauren F Collins, Moira C McNulty, Matthew D Hickey, Mallory O Johnson, Aaloke Mody, et al.

    Among underserved people with HIV with a median of one year of long-acting cabotegravir-rilpivirine use, including those starting with viremia due to adherence challenges, we found higher satisfaction and lower treatment burden compared to daily oral ART, although nearly half preferred another dosing modality and/or a longer dosing interval.

  • Open Access

    Trends in HIV Viral Suppression in the POP-UP Low-Barrier Care Program for People With HIV Experiencing Homelessness or Unstable Housing

    by Elizabeth Imbert, Lisa Fleming, Jon Oskarsson, Caycee Cullen, Mary Shiels, John Friend, Joi Jackson, Lindsay Felten, Negin Zahedikia, Francis Montgomery, et al.

    Background: Human immunodeficiency virus (HIV) viral suppression remains suboptimal among people with HIV (PWH) facing barriers such as homelessness, substance use, and mental health disorders. In 2019, Ward 86 launched the POP-UP program, a low-barrier HIV care model serving PWH with unstable housing and difficulty engaging in care. In 2021, we introduced long-acting antiretroviral therapy (LA-ART), including for PWH unable to attain viral suppression on oral antiretroviral therapy. This study evaluates temporal trends in viral suppression and mortality rates within the POP-UP program. Methods: We conducted a retrospective cohort study of PWH enrolled in the POP-UP program between August 2019 and December 2024. Eligibility included viremia (HIV viral load ≥200 copies/mL) or being off antiretroviral therapy, homelessness/unstable housing, and difficulty engaging in care. Criteria later expanded to include PWH with severe mental health or substance use disorders. The primary outcomes were viral suppression (<200 copies/mL) and death. Results: Among 241 PWH ever enrolled in POP-UP, 86% attained viral suppression at least once during follow-up. Cross-sectional viral suppression was 47% in August 2019 (8 months after program inception) and increased to 64% in December 2024. By December 2024, 46% of suppressed patients were on LA-ART. The mortality rate declined from 8.8/100 person-years in 2020 to 2.6/100 person-years in 2024, with reductions in both AIDS-related and overdose deaths. Conclusions: The POP-UP program improved viral suppression and may have reduced the mortality rate among PWH with substantial barriers to care. Improvements were likely driven by integration of LA-ART and continued quality improvement. Persistent viremia within the program highlights the need for additional strategies to address structural and psychosocial barriers.

  • Open Access

    Discontinuation of Long-acting Injectable Cabotegravir–Rilpivirine in a Large Clinic Cohort

    by Katerina A Christopoulos, Xavier Erguera, Janet Grochowski, Matthew Hickey, Elizabeth Imbert, Samantha Dilworth, Ayesha Appa, Chesa Cox, Mary Shiels, Jon Oskarsson, et al.

    Little is known about long-acting injectable cabotegravir-rilpivirine discontinuation outside clinical trials. In a large clinic cohort, 1 in 6 people with HIV discontinued long-acting injectable cabotegravir-rilpivirine over a median of ∼18 months. Injection-related pain was common. Virologic failure and efficacy concerns drove discontinuation for people with HIV with adherence challenges. Most had viral suppression on alternate antiretrovirals post-discontinuation.


  • Unpacking the “backpack of shame”: Exploring intersections of stigma among Latinx people living with HIV in San Francisco, CA.

    by Edda I. Santiago-Rodríguez, Catherine E. Rivas, Andrés Maiorana, Ashley E. Pérez, Xavier Erguera, Mallory O. Johnson, Katerina A. Christopoulos, Carina Marquez, John A. Sauceda

    Ending the HIV epidemic requires addressing structural determinants of health, including stigma. In this qualitative study, we applied an intersectional framework to study various forms of stigma among Latinx people living with HIV (PLWH). We conducted focus groups and individual interviews with Spanish- and English-speaking Latinx PLWH (N = 19) at an HIV safety-net clinic in San Francisco, California. Using thematic analysis, we identified co-occurring forms of stigma impacting the participants' lives. Participants described the weight of co-occuring stigma related to their multiple identities, including homophobia and HIV-related stigma, both of which participants experienced in the U.S. and in their Latin American home countries. Importantly, many participants faced anti-immigrant stigma in their day-to-day interactions, which manifested as structural inequities such as difficulty finding stable housing and employment. Our findings illustrate experiences of intersectional stigma and systems of oppression. They can be used to inform policies that address social exclusion, discrimination, and stigma among Latinx PLWH. (PsycInfo Database Record (c) 2021 APA, all rights reserved).


  • Open Access

    A Mobile Health App (WYZ) for Engagement in Care and Antiretroviral Therapy Adherence Among Youth and Young Adults Living With HIV: Single-Arm Pilot Intervention Study

    by Parya Saberi, Nadra E Lisha, Xavier A Erguera, Estie Sid Hudes, Mallory O Johnson, Theodore Ruel, Torsten B Neilands

    Background: Youth are globally recognized as being vulnerable to HIV. Younger age has been correlated with worse health outcomes. Mobile health (mHealth) interventions have the potential to interact with youth where they are, using a device they already access. Objective: Using predefined benchmarks, we sought to evaluate the feasibility and acceptability of WYZ, an mHealth app, for improved engagement in care and antiretroviral therapy (ART) adherence among youth and young adults living with HIV. WYZ was designed and developed with input from youth and young adults living with HIV using a human-centered design approach and was based on the information, motivation, and behavioral skills framework to address common barriers to care and ART adherence among youth and young adults living with HIV. Methods: We recruited youth and young adults living with HIV (18-29 years old) from the San Francisco Bay Area to take part in a 6-month pilot trial. Their participation included completing baseline and exit surveys, and participating in seven phone check-ins about their use of WYZ. Results: Youth and young adults living with HIV (N=79) reported high levels of feasibility and acceptability with WYZ use. We met predefined benchmarks for recruitment (79/84, 94%), mean logins per week (5.3), tracking ART adherence (5442/9393, 57.9%), posting chat topics per week (4.8), and app crashes reported per week (0.24). The ease of app download, install, and setup, and comfort with security, privacy, and anonymity were highly rated (all over 91%). Additionally, participants reported high satisfaction for a research project that was remotely conducted. Participants used the app for shorter timeframes compared to the predefined benchmark. Conclusions: We noted high feasibility and acceptability with WYZ. Further research to examine the efficacy of WYZ will enable youth and young adults living with HIV and their providers to make informed decisions when using, recommending, and prescribing the app for improved engagement in HIV care and ART adherence. Trial Registration: ClinicalTrials.gov NCT03587857; https://clinicaltrials.gov/ct2/show/NCT03587857


  • Open Access

    A Mobile Health App (WYZ) for Engagement in Care and Antiretroviral Therapy Adherence Among Youth and Young Adults Living With HIV: Single-Arm Pilot Intervention Study (Preprint)

    by Parya Saberi, Nadra E Lisha, Xavier A Erguera, Estie Sid Hudes, Mallory O Johnson, Theodore Ruel, Torsten B Neilands

    BACKGROUND Youth are globally recognized as being vulnerable to HIV. Younger age has been correlated with worse health outcomes. Mobile health (mHealth) interventions have the potential to interact with youth where they are, using a device they already access. OBJECTIVE Using predefined benchmarks, we sought to evaluate the feasibility and acceptability of WYZ, an mHealth app, for improved engagement in care and antiretroviral therapy (ART) adherence among youth and young adults living with HIV. WYZ was designed and developed with input from youth and young adults living with HIV using a human-centered design approach and was based on the information, motivation, and behavioral skills framework to address common barriers to care and ART adherence among youth and young adults living with HIV. METHODS We recruited youth and young adults living with HIV (18-29 years old) from the San Francisco Bay Area to take part in a 6-month pilot trial. Their participation included completing baseline and exit surveys, and participating in seven phone check-ins about their use of WYZ. RESULTS Youth and young adults living with HIV (N=79) reported high levels of feasibility and acceptability with WYZ use. We met predefined benchmarks for recruitment (79/84, 94%), mean logins per week (5.3), tracking ART adherence (5442/9393, 57.9%), posting chat topics per week (4.8), and app crashes reported per week (0.24). The ease of app download, install, and setup, and comfort with security, privacy, and anonymity were highly rated (all over 91%). Additionally, participants reported high satisfaction for a research project that was remotely conducted. Participants used the app for shorter timeframes compared to the predefined benchmark. CONCLUSIONS We noted high feasibility and acceptability with WYZ. Further research to examine the efficacy of WYZ will enable youth and young adults living with HIV and their providers to make informed decisions when using, recommending, and prescribing the app for improved engagement in HIV care and ART adherence. CLINICALTRIAL ClinicalTrials.gov NCT03587857; https://clinicaltrials.gov/ct2/show/NCT03587857